CAR-T and engineered T cell therapies

Clinical MedicineUpdated Aug 20, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

4 papers

Active filtersClassification:Supporting

Showing 1-4 of total 4 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2020CrossrefSupporting evidence700 citations

TIGIT in cancer immunotherapy

Joe-Marc Chauvin; Hassane M Zarour

Sep 1, 2020Journal for ImmunoTherapy of Cancer

2020OpenAlexSupporting evidence1,470 citations

CRISPR-engineered T cells in patients with refractory cancer

Edward A. Stadtmauer; Joseph A. Fraietta; Megan M. Davis; Adam D. Cohen; Kristy Weber; Eric Lancaster; Patricia Mangan; Irina Kulikovskaya; Minnal Gupta; Fang Chen; Lifeng Tian; Vanessa Gonzalez; Jun Xu; In-Young Jung; J. Joseph Melenhorst; Gabriela Plesa; Joanne Shea; Tina Matlawski; Amanda Cervini; Avery L. Gaymon; Stephanie Desjardins; Anne Lamontagne; January Salas-McKee; Andrew D. Fesnak; Donald L. Siegel; Bruce L. Levine; Julie K. Jadlowsky; Regina M. Young; Anne Chew; Wei‐Ting Hwang; Elizabeth O. Hexner; Beatriz M. Carreno; Christopher L. Nobles; Frederic D. Bushman; Kevin R. Parker; Yanyan Qi; Ansuman T. Satpathy; Howard Y. Chang; Yangbing Zhao; Simon F. Lacey; Carl H. June

Feb 6, 2020Science

2018OpenAlexSupporting evidence3,172 citations

CAR T cell immunotherapy for human cancer

Carl H. June; Roddy S. O’Connor; Omkar U. Kawalekar; Saba Ghassemi; Michael C. Milone

Mar 22, 2018Science